标题
Quantifying CDK inhibitor selectivity in live cells
作者
关键词
-
出版物
Nature Communications
Volume 11, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-06-02
DOI
10.1038/s41467-020-16559-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Quantifying Target Occupancy of Small Molecules Within Living Cells
- (2020) M.B. Robers et al. Annual Review of Biochemistry
- Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7
- (2019) Shanhu Hu et al. CANCER RESEARCH
- Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
- (2019) Ann Lin et al. Science Translational Medicine
- A Photoaffinity Displacement Assay and Probes to Study the Cyclin-Dependent Kinase Family
- (2019) Emma K. Grant et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)
- (2019) Concepción Sánchez-Martínez et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
- (2018) Hetal Patel et al. MOLECULAR CANCER THERAPEUTICS
- Kinase inhibitors: the road ahead
- (2018) Fleur M. Ferguson et al. NATURE REVIEWS DRUG DISCOVERY
- How selective are pharmacological inhibitors of cell cycle-regulating cyclin-dependent kinases?
- (2018) Radek Jorda et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
- (2018) Solomon Tadesse et al. JOURNAL OF MEDICINAL CHEMISTRY
- Binding Kinetics Survey of the Drugged Kinome
- (2018) Victoria Georgi et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors
- (2018) Meiyang Xi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes
- (2017) Qian Zhao et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Inhibitors of cyclin-dependent kinases as cancer therapeutics
- (2017) Steven R. Whittaker et al. PHARMACOLOGY & THERAPEUTICS
- Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
- (2017) Raquel Torres-Guzmán et al. Oncotarget
- Progress towards a public chemogenomic set for protein kinases and a call for contributions
- (2017) David H. Drewry et al. PLoS One
- Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9
- (2016) Pelin Ayaz et al. ACS Chemical Biology
- Effects of target binding kinetics onin vivodrug efficacy: koff, konand rebinding
- (2016) Georges Vauquelin BRITISH JOURNAL OF PHARMACOLOGY
- Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
- (2016) Peng Wu et al. DRUG DISCOVERY TODAY
- Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19
- (2016) Aurélie Mallinger et al. JOURNAL OF MEDICINAL CHEMISTRY
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
- (2016) C Yang et al. ONCOGENE
- Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8
- (2016) Philippe Bergeron et al. ACS Medicinal Chemistry Letters
- Type II Inhibitors Targeting CDK2
- (2015) Leila T. Alexander et al. ACS Chemical Biology
- NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells
- (2015) Andrew S. Dixon et al. ACS Chemical Biology
- A Novel CDK7 Inhibitor of the Pyrazolotriazine Class Exerts Broad-Spectrum Antiviral Activity at Nanomolar Concentrations
- (2015) Corina Hutterer et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
- (2015) Concepción Sánchez-Martínez et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Translating slow-binding inhibition kinetics into cellular and in vivo effects
- (2015) Grant K Walkup et al. Nature Chemical Biology
- A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease
- (2015) Trevor Dale et al. Nature Chemical Biology
- Application of BRET to monitor ligand binding to GPCRs
- (2015) Leigh A Stoddart et al. NATURE METHODS
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Target engagement and drug residence time can be observed in living cells with BRET
- (2015) Matthew B. Robers et al. Nature Communications
- A novel small-molecule MRCK inhibitor blocks cancer cell invasion
- (2014) Mathieu Unbekandt et al. Cell Communication and Signaling
- Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
- (2014) Nicholas Kwiatkowski et al. NATURE
- Cyclin-dependent kinases
- (2014) Marcos Malumbres GENOME BIOLOGY
- Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors
- (2013) Tara R. Rheault et al. ACS Medicinal Chemistry Letters
- Cyclin-dependent kinase 5 regulates E2F transcription factor through phosphorylation of Rb protein in neurons
- (2012) Akira Futatsugi et al. CELL CYCLE
- Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
- (2012) Vladimir Krystof et al. CURRENT PHARMACEUTICAL DESIGN
- Comprehensive analysis of kinase inhibitor selectivity
- (2011) Mindy I Davis et al. NATURE BIOTECHNOLOGY
- Rebinding: or why drugs may act longerin vivothan expected from theirin vitrotarget residence time
- (2010) Georges Vauquelin Expert Opinion on Drug Discovery
- The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity
- (2009) S. Ali et al. CANCER RESEARCH
- CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
- (2009) A Pardanani et al. LEUKEMIA
- Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
- (2009) M. S. Squires et al. MOLECULAR CANCER THERAPEUTICS
- Cyclin-dependent kinases: a family portrait
- (2009) Marcos Malumbres et al. NATURE CELL BIOLOGY
- Identification ofN-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design†
- (2008) Paul G. Wyatt et al. JOURNAL OF MEDICINAL CHEMISTRY
- CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
- (2008) Ron Firestein et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started